Evaluation of antitumor activity of peptide extracts from medicinal plants on the model of transplanted breast cancer in CBRB-Rb(8.17)1Iem mice

Bulletin of Experimental Biology and Medicine

Volumn 145, Issue 4, 2008, Pages 464-466

  Tepkeeva, I I ^a   Moiseeva, E V ^a   Chaadaeva, A V ^a   Zhavoronkova, E V ^a   Kessler, Yu V ^a   Semushina, S G ^a   Demushkin, V P ^a  

^a SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

Author keywords

Antitumor activity; CBRB Rb(8.17)1Iem mice; Experimental model of human breast cancer; Plant peptides

Indexed keywords

CHELIDONIUM EXTRACT; EQUISETUM ARVENSE EXTRACT; FRANGULA EXTRACT; GREEN TEA EXTRACT; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; INONOTUS OBLIQUUS EXTRACT; INULA HELENIUM EXTRACT; LAURUS NOBILIS EXTRACT; PEPTIDE DERIVATIVE; PLANT EXTRACT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER GROWTH; CANCER INHIBITION; CANCER TRANSPLANTATION; CONTROLLED STUDY; ELECAMPANE; EQUISETUM ARVENSE; FEMALE; LAURUS NOBILIS; MALE; MEDICINAL PLANT; MOUSE; NONHUMAN; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DRUG EVALUATION, PRECLINICAL; FEMALE; MALE; MICE; MICE, INBRED STRAINS; NEOPLASM TRANSPLANTATION; PEPTIDE FRAGMENTS; PLANT EXTRACTS; PLANTS, MEDICINAL; TIME FACTORS; TRANSPLANTATION, ISOGENEIC; TUMOR BURDEN;

CHELIDONIUM MAJUS; EQUISETUM ARVENSE; FRANGULA; HYPERICUM PERFORATUM; INONOTUS OBLIQUUS; INULA HELENIUM; LAURUS NOBILIS; MUS;

EID: 55649097081     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10517-008-0119-1     Document Type: Article

References (8)

1. E. S. Severin and A. V. Rodina, Uspekhi Biol. Khim., 46, 43-64 (2006).
2. V. V. Starinskii, V. M. Mirabishvilli, O. P. Gretsova, et al., Vopr. Onkol., 49, 422-426 (2003).
3. E. M. Treshchalina, Antitumor Activity of Substances of Natural Origin [in Russian], Moscow (2005).
4. O. V. Shvab, S. V. Trishkin, E. N. Shepel', et al., Bioorgan. Khim., 25, 20-24 (1999).
5. D. J. Craik, M. Cemazar, and N. L. Daly, Curr. Opin. Drug Discov. Devel., 10, No. 2, 176-184 (2007).
6. E. V. Moiseeva, I. B. Merkulova, C. Bijleveld, et al., Cancer Immunol. Immunother., 52, No. 8, 487-496 (2003).
7. E. Svangard, R. Burman, S. Gunasekera, et al., J. Nat. Prod., 70, No. 4, 643-647 (2007).
8. E. Svangard, U. Goransson, Z. Hocaoglu, et al., Ibid., 67, No. 2, 144-147 (2004).